Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)

NCT04745130 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Sintilimab, Cetuximab, Regorafenib,Combine,mCRC

Interventions

DRUG: Sintilimab，regofinib，cetuximab
DRUG: KRAS BRAF mutant Sintilimab + regafinil

Sponsor

Tianjin Medical University Cancer Institute and Hospital